ArticleBMC complementary medicine and therapies2026
Resistance to doxorubicin therapy in breast cancer cells could be attenuated by ligustilide: impact on autophagy and LncRNA H19.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResistance to DOX in breast cancer (BC) treatment is attributed to multiple mechanisms. The potential of autophagy inhibition in mitigating DOX resistance in BC has yet to be clarified. Despite showing anti-tumorigenic activity, the role of ligustilide (LIG) in BC treatment remains limited.
aimTo evaluate LIG-mediated autophagy inhibition in DOX-treated MCF-7, MCF-7/DOX, and MDA-MB-231 cells, and investigate LncRNA H19's role in BC resistance.
methodsThe three cell lines were treated with DOX, LIG, or both of them. Autophagic flux and expression of ERα, metastasis-associated protein (MTA1) complex components, autophagy-related 7 gene (ATG7), multidrug resistance gene 1 (MDR1) and LncRNA H19 were assessed. KEY
findingsBoth individual treatments showed dose-dependent cytotoxicity. When combined together, LIG increased DOX cytotoxicity in MCF-7/DOX and MDA-MB-231. LIG inhibited DOX-induced autophagic flux, indicated by elevated LC3BII and p62 levels, and reversed MDR1 in MCF-7/DOX and MDA-MB-231. LIG monotherapy upregulated ERα in MCF-7/DOX and restored its expression in MDA-MB-231. In MCF-7/DOX, combined treatment upregulated ERα and downregulated LncRNA H19 relative to DOX monotherapy, whereas in MDA-MB-231, it upregulated LncRNA H19 compared with DOX monotherapy.
conclusionLIG mitigated DOX-induced resistance through inhibiting autophagy, restoring ERα expression, and downregulating LncRNA H19 in the DOX-resistant BC cell line, thereby presenting a potential therapeutic approach in BC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.